AUL
VKTX icon

AlphaGrep UK Ltd’s Viking Therapeutics VKTX Stock Holding History

AlphaGrep UK Ltd’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$228K Buy
+7,004
New +$225K 0.07% 656

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

AlphaGrep UK Ltd's VKTX Position: Q1 2026 in Review

AlphaGrep UK Ltd opened a new position in Viking Therapeutics (VKTX) in Q1 2026: 7,004 shares worth $228K. The stake represents 0.07% of the portfolio and ranks #656 among its holdings.

413 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • AlphaGrep UK Ltd held 7,004 shares of Viking Therapeutics worth $228K as of Q1 2026.
  • Viking Therapeutics was a new AlphaGrep UK Ltd position in Q1 2026.
  • Viking Therapeutics made up 0.07% of AlphaGrep UK Ltd's portfolio in Q1 2026, its #656 holding.
  • 413 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.